Complement-Binding Donor-Specific Anti-HLA Antibodies: Biomarker for Immunologic Risk Stratification in Pediatric Kidney Transplantation Recipients
Open Access
- 16 March 2022
- journal article
- research article
- Published by Frontiers Media SA in Transplant International
- Vol. 35, 10158
Abstract
Antibody-mediated rejection is a common cause of early kidney allograft loss but the specifics of antibody measurement, therapies and endpoints have not been universally defined. In this retrospective study, we assessed the performance of risk stratification using systematic donor-specific antibody (DSA) monitoring. Included in the study were children who underwent kidney transplantation between January 1, 2010 and March 1, 2018 at Stanford, with at least 12-months follow-up. A total of 233 patients were included with a mean follow-up time of 45 (range, 9–108) months. Median age at transplant was 12.3 years, 46.8% were female, and 76% had a deceased donor transplant. Fifty-two (22%) formed C1q-binding de novo donor-specific antibodies (C1q-dnDSA). After a standardized augmented immunosuppressive protocol was implemented, C1q-dnDSA disappeared in 31 (58.5%). Graft failure occurred in 16 patients at a median of 54 (range, 5–83) months, of whom 14 formed dnDSA. The 14 patients who lost their graft due to rejection, all had persistent C1q-dnDSA. C1q-binding status improved the individual risk assessment, with persistent; C1q binding yielding the strongest independent association of graft failure (hazard ratio, 45.5; 95% confidence interval, 11.7–177.4). C1q-dnDSA is more useful than standard dnDSA as a noninvasive biomarker for identifying patients at the highest risk of graft failure.Keywords
This publication has 37 references indexed in Scilit:
- Risk of graft loss in adolescent kidney allograft recipientsNature Reviews Nephrology, 2013
- The Role of Immunoglobulin-G Subclasses and C1q in De Novo HLA-DQ Donor-Specific Antibody Kidney Transplantation OutcomesTransplantation, 2013
- Consensus Guidelines on the Testing and Clinical Management Issues Associated With HLA and Non-HLA Antibodies in TransplantationTransplantation, 2013
- Antibody-Mediated Allograft RejectionTransplantation, 2013
- A Temporal Model of Human IgE and IgG Antibody FunctionFrontiers in Immunology, 2013
- Evolution and Clinical Pathologic Correlations of De Novo Donor-Specific HLA Antibody Post Kidney TransplantAmerican Journal of Transplantation, 2012
- Complement‐fixing donor‐specific antibodies identified by a novel C1q assay are associated with allograft lossPediatric Transplantation, 2011
- Subgroup Analyses in Randomized Controlled Trials: The Need for Risk Stratification in Kidney TransplantationAmerican Journal of Transplantation, 2009
- Survival ensemblesBiostatistics, 2005
- Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimationStatistics in Medicine, 2004